PharmTech
CONTINUE TO SITE >

OR WAIT 15 SECS

Pharmaceutical Technology
Spotlight
COVID-19 UpdateAnalyticsDrug DevelopmentManufacturingOutsourcingQuality Systems2020 Bio/Pharma Virtual Congress
Topic
View MoreAnalytical Method DevelopmentAPIsAseptic ProcessingBiologic DrugsDosage FormsDrug DeliveryEquipmentExcipientsFormulationPackagingProcess Control/PATProcess DevelopmentQA/QCRegulatory ActionSupply Chain
News
All NewsTop NewsIndustry NewsBio/Pharma NewsSupplier NewsNews from EuropeEvents
Publications
All PublicationsPharmTechPharmTech Europe
Resources
Front & CenterPharma InsightsSponsored eBooksSponsored PodcastsSponsored VideosWhitepapers
WebcastsMarketplace
Subscribe
EnewslettersMagazine North AmericaMagazine Europe

  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Contacts
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.

Spotlight
  • COVID-19 Update
  • Analytics
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
  • 2020 Bio/Pharma Virtual Congress
TopicSee All >
  • Analytical Method Development
  • APIs
  • Aseptic Processing
  • Biologic Drugs
  • Dosage Forms
  • Drug Delivery
  • Equipment
  • Excipients
  • Formulation
  • Packaging
  • Process Control/PAT
  • Process Development
  • QA/QC
  • Regulatory Action
  • Supply Chain
  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Contacts
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.

Taking Complexity to the Next Level

October 31, 2019
Pharmaceutical Technology Editors
Pharmaceutical Technology Editors

During the Tuesday afternoon (Nov. 5, 2019) at CPhI, Maurits Janssen (senior director, head of commercial development at Lonza) will guide the audience through the complexities and best practices of moving from small molecule to biologics into antibody drug conjugates (ADCs).

During the Tuesday afternoon (Nov. 5, 2019) at CPhI, Maurits Janssen (senior director, head of commercial development at Lonza) will guide the audience through the complexities and best practices of moving from small molecule to biologics into antibody drug conjugates (ADCs).

Approaching drug development with highly potent compounds gives rise to specific challenges, which can ultimately lead to increased costs and complex processes. In his presentation, Janssen will highlight ways in which companies can facilitate rapid time to clinic and market and will use a case study to emphasize the advantages of seamless integration of highly potent API and ADC operations.

HPAPIs and ADCs – a journey through high potencyTuesday Nov. 5, 201913:50–14:20ICSE Theatre (120G43)

 

 

 

 

Related Content:

CPhI NewsIndustry News
website logo

Michael J. Hennessy: MM&M 40 Under 40 Award

website logo

Pfizer and BioNTech Submit New Vaccine Stability Data to FDA

website logo

FDA Gives Guidance on COVID-19 Variants